-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The efficacy of local therapy (LT) in patients with selective metastatic prostate cancer (mPCa) has been confirmed
.
However, the effect between different LT treatments is unclear
The efficacy of local therapy (LT) in patients with selective metastatic prostate cancer (mPCa) has been confirmed
The researchers screened mPCa patients who received RT or RP from 2004 to 2016 from the SEER database
.
Multivariate Cox proportional hazard analysis was used to evaluate the comparative risk of prostate cancer-specific mortality (CSM) and all-cause mortality (ACM) between LT
The researchers screened mPCa patients who received RT or RP from 2004 to 2016 from the SEER database
Before PSM, there were 203 cases in the RT group and 481 cases in the RP group
In the unmatched cohort, the Cox proportional hazards model showed no significant difference between the two groups of CSM or ACM (CSM: HR = 0.
Prognostic analysis
Prognostic analysisThe Kaplan-Meier survival curve showed that the 10-year survival rates of the RP and RT groups before PSM were 70.
5% vs.
56.
7% for CSS and 55.
8% vs.
37.
0% for OS
.
After PSM, the 10-year incidence of CSS for RT and RT were 73.
The Kaplan-Meier survival curve showed that the 10-year survival rates of the RP and RT groups before PSM were 70.
Comparison of CSS and OS before and after PSM
Comparison ofCSS and OS before and after PSMIn the subgroup analysis, PR treatment in the T1-2 subgroup was associated with lower CSM (HR = 0.
42, 95%CI = 0.
17-0.
99, p = 0.
048)
.
In the subgroups of patients with GS≤7 and PSA≤20 ng/ml, the difference in CSM between the two groups was close to statistically significant (HR = 0.
In the subgroup analysis, PR treatment in the T1-2 subgroup was associated with lower CSM (HR = 0.
Subgroup analysis
Subgroup analysisIn summary, studies have shown that for mPCa patients with good primary tumor characteristics, RP has a better survival outcome than RT, but not for more advanced patients
.
.
Studies have shown that for mPCa patients with good primary tumor characteristics, RP has a better survival outcome than RT, but not for more advanced patients
Original source:
Guo X, Xia H, Su X, Hou H, Zhong Q and Wang J (2021) Comparing the Survival Outcomes of Radical Prostatectomy Versus Radiotherapy for Patients With De Novo Metastasis Prostate Cancer: A Population-Based Study.
Front.
Oncol.
11: 797462.
doi: 10.
3389/fonc.
2021.
797462
Front.
Oncol.
11: 797462.
doi: 10.
3389/fonc.
2021.
797462 leave a message here